{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T06:27:53Z","timestamp":1788589673003,"version":"build-2803163510"},"reference-count":39,"publisher":"Elsevier BV","issue":"18","license":[{"start":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T00:00:00Z","timestamp":1177977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2007,5]]},"DOI":"10.1016\/j.vaccine.2007.01.088","type":"journal-article","created":{"date-parts":[[2007,2,6]],"date-time":"2007-02-06T07:56:16Z","timestamp":1170748576000},"page":"3669-3678","source":"Crossref","is-referenced-by-count":34,"title":["Enhanced decision support for policy makers using a web interface to health-economic models\u2014Illustrated with a cost-effectiveness analysis of nation-wide infant vaccination with the 7-valent pneumococcal conjugate vaccine in the Netherlands"],"prefix":"10.1016","volume":"25","author":[{"given":"G.A.A.","family":"Hubben","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Bos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.M.","family":"Glynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"van der Ende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"van Alphen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"Postma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.vaccine.2007.01.088_bib1","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.vaccine.2004.06.019","article-title":"Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in the Netherlands and its impact on decision-making","volume":"23","author":"Welte","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2007.01.088_bib2","unstructured":"Health council of the Netherlands. Vaccination of infants against pneumococcal infections. The Hague: Health council of the Netherlands; 2005."},{"issue":"6","key":"10.1016\/j.vaccine.2007.01.088_bib3","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1093\/clinids\/21.6.1390","article-title":"Pneumococcal meningitis in children: prognostic indicators and outcome","volume":"21","author":"Kornelisse","year":"1995","journal-title":"Clin Infect Dis"},{"issue":"435","key":"10.1016\/j.vaccine.2007.01.088_bib4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1651-2227.2000.tb00776.x","article-title":"Epidemiology of invasive and other pneumococcal disease in children in England and Wales 1996\u20131998","volume":"89","author":"Miller","year":"2000","journal-title":"Acta Paediatr Suppl"},{"issue":"5","key":"10.1016\/j.vaccine.2007.01.088_bib5","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/00006454-199305000-00008","article-title":"Outcomes of bacterial meningitis in children: a meta-analysis","volume":"12","author":"Baraff","year":"1993","journal-title":"Pediatr Infect Dis J"},{"issue":"7312","key":"10.1016\/j.vaccine.2007.01.088_bib6","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/bmj.323.7312.533","article-title":"Meningitis in infancy in England and Wales: follow up at age 5 years","volume":"323","author":"Bedford","year":"2001","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.vaccine.2007.01.088_bib7","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3201\/eid0204.9604","article-title":"New vaccines for the prevention of pneumococcal infections","volume":"2","author":"Kayhty","year":"1996","journal-title":"Emerg Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2007.01.088_bib8","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S0264-410X(00)00271-1","article-title":"The burden of otitis media","volume":"19","author":"Klein","year":"2000","journal-title":"Vaccine"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2007.01.088_bib9","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1016\/S0264-410X(00)00284-X","article-title":"Assessing costs and cost effectiveness of pneumococcal disease and vaccination within Kaiser Permanente","volume":"19","author":"Black","year":"2000","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2007.01.088_bib10","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2165\/00019053-200321080-00005","article-title":"Cost effectiveness of pneumococcal vaccination for infants and children with the conjugate vaccine PnC-7 in Germany","volume":"21","author":"Claes","year":"2003","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"10.1016\/j.vaccine.2007.01.088_bib11","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1086\/345833","article-title":"A pharmacoeconomic evaluation of 7-valent pneumococcal conjugate vaccine in Canada","volume":"36","author":"Lebel","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"31\u201332","key":"10.1016\/j.vaccine.2007.01.088_bib12","doi-asserted-by":"crossref","first-page":"4203","DOI":"10.1016\/j.vaccine.2004.05.003","article-title":"Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales","volume":"22","author":"Melegaro","year":"2004","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2007.01.088_bib13","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00006454-200003000-00003","article-title":"Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group","volume":"19","author":"Black","year":"2000","journal-title":"Pediatr Infect Dis J"},{"issue":"4","key":"10.1016\/j.vaccine.2007.01.088_bib14","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1586\/14760584.3.4.433","article-title":"Cost-effectiveness studies of pneumococcal conjugate vaccines","volume":"3","author":"McIntosh","year":"2004","journal-title":"Expert Rev Vaccines"},{"issue":"14","key":"10.1016\/j.vaccine.2007.01.088_bib15","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/j.vaccine.2004.09.029","article-title":"Immunogenicity, safety and tolerability of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months post-natally to pre- and full-term infants","volume":"23","author":"Esposito","year":"2005","journal-title":"Vaccine"},{"issue":"18","key":"10.1016\/j.vaccine.2007.01.088_bib16","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa022823","article-title":"Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine","volume":"348","author":"Whitney","year":"2003","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.vaccine.2007.01.088_bib17","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1016\/S0149-2918(03)80322-3","article-title":"Epidemiologic impact and cost-effectiveness of universal infant vaccination with a 7-valent conjugated pneumococcal vaccine in the Netherlands","volume":"25","author":"Bos","year":"2003","journal-title":"Clin Ther"},{"key":"10.1016\/j.vaccine.2007.01.088_bib18","unstructured":"Netherlands Reference Laboratory for Bacterial Meningitis. Bacterial Meningitis in the Netherlands: Annual Report 1996\u20132001. Amsterdam, the Netherlands: University of Amsterdam; 2001."},{"issue":"4\u20135","key":"10.1016\/j.vaccine.2007.01.088_bib19","first-page":"339","article-title":"Postmarketing surveillance based on electronic patient records: the IPCI project","volume":"38","author":"Vlug","year":"1999","journal-title":"Methods Inf Med"},{"key":"10.1016\/j.vaccine.2007.01.088_bib20","unstructured":"PRISMANT Health Care. National Medical Registration of Dutch Hospitals [in Dutch]. Utrecht, the Netherlands: SIG Healthcare; 1996."},{"key":"10.1016\/j.vaccine.2007.01.088_bib21","unstructured":"Netherlands Reference Laboratory for Bacterial Meningitis. Bacterial Meningitis in the Netherlands: Annual Reports 2001\u20132004. Amsterdam, the Netherlands: University of Amsterdam; 2004."},{"issue":"435","key":"10.1016\/j.vaccine.2007.01.088_bib22","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1651-2227.2000.tb00778.x","article-title":"Epidemiology of meningitis and bacteraemia due to Streptococcus pneumoniae in the Netherlands","volume":"89","author":"Spanjaard","year":"2000","journal-title":"Acta Paediatr Suppl"},{"issue":"4","key":"10.1016\/j.vaccine.2007.01.088_bib23","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/00006454-200004000-00032","article-title":"Etiology and treatment of pneumonia","volume":"19","author":"McCracken","year":"2000","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2007.01.088_bib24","unstructured":"Oostenbrink J.B., Bouwmans CAM, Koopmanschap MA, Rutten FFH. Manual for costing research. Methods and Reference Prices for Economic Evaluation in Healthcare [in Dutch]. Amstelveen, The Netherlands: College of Health Care Insurance; 2004."},{"issue":"2","key":"10.1016\/j.vaccine.2007.01.088_bib25","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2165\/00019053-200018020-00005","article-title":"Differences in attitudes, knowledge and use of economic evaluations in decision-making in the Netherlands. The Dutch results from the EUROMET project","volume":"18","author":"Zwart-van Rijkom","year":"2000","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"10.1016\/j.vaccine.2007.01.088_bib26","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1093\/clinids\/10.2.446","article-title":"Pneumococcal bacteremia in adults over a 10-year period at University Hospital, Leiden","volume":"10","author":"Bruyn","year":"1988","journal-title":"Rev Infect Dis"},{"issue":"18","key":"10.1016\/j.vaccine.2007.01.088_bib27","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1056\/NEJMoa040845","article-title":"Clinical features and prognostic factors in adults with bacterial meningitis","volume":"351","author":"van de Beek","year":"2004","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.vaccine.2007.01.088_bib28","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1097\/00006454-200209000-00005","article-title":"Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia","volume":"21","author":"Black","year":"2002","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2007.01.088_bib29","unstructured":"Bos JM, Rumke HC, Welte R. Cost-Effectiveness of Vaccination Against Pneumococcal and Meningococcal Infections in Children [in Dutch]. Bilthoven, the Netherlands: National Institute of Public Health & the Environment; 2000."},{"key":"10.1016\/j.vaccine.2007.01.088_bib30","unstructured":"Gruteke P, Postma MJ, Grosheide PM. Prevention of Congenital Syphilis: Economic Evaluation Using Surveillance of the Public-Health Laboratories [in Dutch]. Bilthoven, the Netherlands: National Institute of Public Health & the Environment; 1995."},{"key":"10.1016\/j.vaccine.2007.01.088_bib31","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3109\/00365549609027149","article-title":"Clinical manifestation and course of meningococcal disease in 562 patients","volume":"28","author":"Schildkamp","year":"1996","journal-title":"Scand J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2007.01.088_bib32","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2165\/00019053-200017050-00006","article-title":"Handling uncertainty in cost-effectiveness models","volume":"17","author":"Briggs","year":"2000","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"10.1016\/j.vaccine.2007.01.088_bib33","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/hec.4730030505","article-title":"Costs, effects and C\/E-ratios alongside a clinical trial","volume":"3","author":"van Hout","year":"1994","journal-title":"Health Econ"},{"issue":"4","key":"10.1016\/j.vaccine.2007.01.088_bib34","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1177\/027298902400448867","article-title":"Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease","volume":"22","author":"Briggs","year":"2002","journal-title":"Med Decis Making"},{"key":"10.1016\/j.vaccine.2007.01.088_bib35","unstructured":"HHS-CDC NEWS: Direct and Indirect Effects of Routine Vaccination of Children with 7-Valent Pneumococcal Conjugate Vaccine on Incidence of Invasive Pneumococcal Disease-US, 1998\u20132003. Ann Pharmacother 2005;39(11):1967\u20138."},{"issue":"1","key":"10.1016\/j.vaccine.2007.01.088_bib36","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1586\/14737167.5.1.59","article-title":"Towards a healthier discount procedure","volume":"5","author":"Klok","year":"2005","journal-title":"Exp Rev Pharmacoeconomics Outcomes"},{"issue":"1","key":"10.1016\/j.vaccine.2007.01.088_bib37","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1524-4733.2003.00234.x","article-title":"Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices-Modeling Studies","volume":"6","author":"Weinstein","year":"2003","journal-title":"Value Health"},{"issue":"25\u201326","key":"10.1016\/j.vaccine.2007.01.088_bib38","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1016\/j.vaccine.2004.03.001","article-title":"Potential conflicts of interest in vaccine economics research: a commentary with a case study of pneumococcal conjugate vaccination","volume":"22","author":"Beutels","year":"2004","journal-title":"Vaccine"},{"issue":"13","key":"10.1016\/j.vaccine.2007.01.088_bib39","doi-asserted-by":"crossref","first-page":"857","DOI":"10.2165\/00019053-200422130-00004","article-title":"A decision chart for assessing and improving the transferability of economic evaluation results between countries","volume":"22","author":"Welte","year":"2004","journal-title":"Pharmacoeconomics"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X07000862?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X07000862?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,9]],"date-time":"2019-01-09T07:22:04Z","timestamp":1547018524000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X07000862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5]]},"references-count":39,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["S0264410X07000862"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2007.01.088","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2007,5]]}}}